Explore our SITC Presentation

About Us

MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. iNKTs have a dual-mechanism of action with an internal targeting and homing device (iTCR) that modulates both arms of immunity, innate and adaptive. iNKTs combine the killing features of natural killer (NK) cells with the durable memory response of T cells. iNKT cells have been demonstrated to be highly effective in treating solid tumor cancers in their native form and MiNK has demonstrated that these cells can be further engineered or edited for super-targeting.

Executive Leadership

X

Scientific Advisory Board

Board of Directors

Management

Robert Stein, M.D., Ph.D.

Scientific Advisor

Robert Stein, M.D., Ph.D.
Scientific Advisor

Manuel Hidalgo, M.D., Ph.D.

Scientific Advisor

Manuel Hidalgo, M.D., Ph.D.
Scientific Advisor

Mark Exley, Ph.D.

Scientific Advisor

Mark Exley, Ph.D.
Scientific Advisor

Jenny Gumperz, Ph.D.

Scientific Advisor

Jenny Gumperz, Ph.D.
Scientific Advisor

Lydia Lynch, Ph.D.

Scientific Advisor

Lydia Lynch, Ph.D.
Scientific Advisor

Marcela Maus, M.D., Ph.D.

Scientific Advisor

Marcela Maus, M.D., Ph.D.
Scientific Advisor

Garo Armen, Ph.D.

Chairman

Garo Armen, Ph.D.
Chairman

Peter Behner

Director

Peter Behner
Director

Jennifer Buell, Ph.D.

President and CEO

Jennifer Buell, Ph.D.
President and CEO

Brian Corvese

Director

Brian Corvese
Director

Barbara Ryan

Director

Barbara Ryan
Director

Ulf Wiinberg

Director

Ulf Wiinberg
Director

Jennifer Buell, Ph.D.

President and CEO

Jennifer Buell, Ph.D.
President and CEO

Marc Van Dijk, Ph.D.

Chief Scientific Officer

Marc Van Dijk, Ph.D.
Chief Scientific Officer

Heather Boussios

General Counsel and Chief Compliance Officer

Heather Boussios
General Counsel and Chief Compliance Officer

Joy Zhou, Ph.D.

Vice President, Head of CMC

Joy Zhou, Ph.D.
Vice President, Head of CMC

Thiago Favano

Senior Director, Portfolio Operations

Thiago Favano
Senior Director, Portfolio Operations

Pipeline

MiNK's lead product candidate AGENT-797 is in multiple Phase 1 clinical trials with clinical and preclinical readouts anticipated later this year. Our research team is focused on developing potential first-or best-in-class therapies using a next- generation technology platform to develop novel engineered iNKT cell therapies and bispecific iNKT cell engagers.

Target/Indication

Product

Pre-clinical

Phase 1/2

Next milestone

Native iNKT Cells

Oncology

Solid Tumors +/- anti-PD1

AGENT-797

Early clinical

2023
Updated data at SITC

Gastric Cancer + SOC
+/- BOT/BAL

AGENT-797

Early clinical

2023
Trial Initiation

Immune-mediated diseases

Acute Respiratory Distress Syndrome (ARDS)

AGENT-797

Early clinical

2023
Updated data at ATS

Engineered iNKT Cells

Oncology

FAP-CAR-iNKT

MiNK-215

Pre-clinical

2023
Potential IND filing 2024 &
Updated data at ASGCT 2023

BCMA-CAR-iNKT

MiNK-413

Pre-clinical

2024
IND Ready

PRAME TCR

MiNK-PRAME-TCR

Pre-clinical

2024
Candidate nomination

Undisclosed

MiNK-Engagers

Pre-clinical

2024
Candidate nomination

*Autologous T cell program IND-ready: allogeneic iNKT program in development